Development Obligations. 1. The College supports the development, production, and dissemination of copyrightable, trademarkable, patentable, and other intellectual properties by its employees.
Development Obligations i. The Lessee shall develop the Project as per the Development Milestones specified in Article
Development Obligations. 1. The College supports the development, production, and dissemination of intellectual property by its faculty members so long as those efforts support and do not detract from faculty member’s job duties.
Development Obligations. 5.1 Development period and Milestone to be achieved by the Developer are as per details below:
Development Obligations. In exchange for CC Trust’s assistance in facilitating the financing of the Anchor Project, CC Trust shall cause the Anchor Project to be constructed on the Property, at no expense to NTIFA (other than the Public Assistance as provided in Article V herein). The Anchor Project must be constructed in accordance with the Phasing Plan and Development Plans approved by NTIFA, acting in its reasonable discretion, not to be unreasonably withheld, conditioned or delayed. CC Trust shall secure, or cause the appropriate parties to secure, all governmental approvals in connection with (a) the preparation of the Property for construction; (b) the construction, completion, and occupancy of the Anchor Project; and (c) the development and operation of the Anchor Project, including, without limitation, zoning, building code, and environmental laws.
Development Obligations. The Landowner shall cause the Mixed Use Project to be constructed on the Property, at no expense to NTIFA (other than the Public Assistance to secure construction of the Anchor Project as provided in Article V herein). The Mixed Use Project must be constructed in accordance with the Phasing Plan and Development Plans approved by NTIFA, acting in its reasonable discretion, not to be unreasonably withheld, conditioned or delayed. The Landowner shall secure or cause the appropriate parties to secure all governmental approvals in connection with (a) the preparation of the Property for construction; (b) the construction, completion, and occupancy of the Mixed Use Project; and (c) the development and operation of the Mixed Use Project, including, without limitation, zoning, building code, and environmental laws. The Landowner will dedicate up to 1,200 square feet within the Property for public art.
Development Obligations. You agree to do each of the following:
Development Obligations i. The Licensee shall develop the Project as per the Development Milestones specified in Article 2.8 and approved designs and drawings, in accordance with the timelines set forth in the Agreement.
Development Obligations. 9.1 The Licensee shall use its reasonable endeavours to develop, exploit and Market the Licensed Product in accordance with the Development Plan.
Development Obligations. Each Party shall be responsible for carrying out its activities in accordance with the Development Plan. These activities shall include, without limitation (i) identifying and carrying out all major Development tasks to be conducted prior to submission of filings for Regulatory Approval of a Collaboration Product for a particular indication; (ii) identifying key Development objectives, expected associated resources, risk factors, timelines, go/no go decision points and relevant decision criteria; (iii) carrying out all aspects of (e.g., designing studies and protocols and conducting), and preparing the associated Regulatory Plan for, all clinical trials necessary to obtain Regulatory Approval for each indication pursued, as well as establishing new dosage forms, new formulations or other enhancements of approved Collaboration Products (but excluding Post-Approval Clinical Studies) including, but not limited to (1) establishing/contracting with clinical sites, investigators and contract research organizations ("CROs"), (2) enrolling clinical study patients, (3) organizing investigator meetings, scientific meetings, advisory panel workshops and regulatory meetings, and (4) analyzing, summarizing and presenting clinical study results; (iv) performing any other additional research and pre-clinical research in support of the clinical development of Collaboration Products; (v) forecasting clinical manufacturing production requirements; and (vi) Regulatory Authority reporting on study design, study outcome, other communications and regulatory filings (to the extent not covered by a Regulatory Plan).
